Triple-negative breast cancers (TNBCs), which lack expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), account for approximately 10 to 17% of all breast cancers [1-3] and are associated with relatively poor clinical outcomes. This evidence concerns the gene PGR and breast cancer.